Capture the participants who never come in. Without building the pipeline.
Multi-device collection from wherever your participants actually are, with provenance on every value and delivery structured for your analysis pipeline. The sponsor funds the instance. The site runs the study without standing up compliance infrastructure for one trial.
A custom pipeline for every trial, and a build no site wants.
Continuous-monitoring and multi-device studies usually mean standing up a custom ingestion-and-compliance pipeline for every trial, and asking the provider site to build and run infrastructure it never wanted. A one-study integration costs a site roughly what a whole-organization integration costs, so sites decline studies or the design gets degraded to avoid the work. That friction slows enrollment and scares off sites, and it's exactly the kind of infrastructure a sponsor shouldn't have to build to run one study.
The signal, and the story of where it came from.
Your participant app, or ours
The SDK goes into the app you already ship, so participants are not asked to install a second one. If you would rather not build a participant-facing surface, use ours.
Whatever the protocol calls for
A catalog of 60+ FDA-cleared cellular devices, plus any BLE sensor via the SDK. Studies rarely use one vendor's hardware, and a neutral platform collects across all of it.
Provenance on every value
Each observation carries where it came from, when, and which version of which algorithm produced it, so a value stays defensible long after the study closes.
Participants kept on pace
The same agents that keep patients on pace in care can keep participants on protocol between visits, so a coordinator is not calling to chase a missing reading.
The sponsor funds the instance.
The rail below is the whole model. The site stays the covered entity, as it always was, with AnyBio operating as its business associate under BAA, and the sponsor funds the instance. What the site does not do is build, fund or run the pipeline for one study. Data lands structured for the sponsor's analysis pipeline, timestamped, attributed and auditable. (On regulatory scope: we provide auditable, provenance-tracked, access-controlled collection; for FDA-regulated trials with specific electronic-records requirements, for example 21 CFR Part 11, or GCP obligations, we'll walk through what applies to your study and where responsibilities sit. We don't overstate formal regulatory-trial certification we haven't established.)
YOUR DEVICES
CLINICAL SYSTEMS
SPONSOR FUNDS THE INSTANCE
TRIAL DEVICES CAPTURED
BAA WITH THE SITE
GOVERNED EXPORT TO SPONSOR
FHIR / HL7V2 WITH PROVENANCE
YOUR DEVICES
CLINICAL SYSTEMS
We are a component, not your study platform.
Your protocol, your sponsor, your sites, your analysis pipeline and whatever study platform you already run all stay exactly where they are. We are not asking you to move a trial onto us, and we are not going to tell you we do eConsent, randomization, EDC or a trial master file, because we don't. What we do is the part that is genuinely hard to build and easy to underestimate: capturing high-fidelity signal from people at home, keeping its provenance intact, and handing it to you in a shape your analysis can use.
That is a narrower promise than a platform makes, and it is the reason it can be kept.
Matched with a provider site through our research channel.
If you have a study but not a provider site to run it, our research channel can help. Through it, we can route you toward a provider site and stand the study up on AnyBio's rails, sponsor-funded, compliant, and auditable, so both you and the site participate without building the pipeline. (This is a path we can help open, not a guaranteed match; we'll talk through what fits your study.)
The trial is the entry. The rails stay.
Trials rarely use one vendor's device, so a neutral platform collects across whatever the protocol needs. And the trial is an entry, not a dead end: the same rails the study runs on can carry forward into ongoing research or clinical use if the site wants to keep going after the study ends. A device or a model moves from proving to deploying on the same platform, without a second integration. That path is the same one technology partners come in on.
Talk to us about your study's data collection.
For sponsors and CROs running multi-device or continuous-monitoring studies who want compliant, auditable collection without building it, whether or not you have a provider site yet.
